Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.

about

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.

Item

http://www.wikidata.org/entity/Q55345557

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Efficacy and safety profile of ...... port on the emerging new data.

@en

Efficacy and safety profile of ...... port on the emerging new data.

@nl

type

Item

label

Efficacy and safety profile of ...... port on the emerging new data.

@en

Efficacy and safety profile of ...... port on the emerging new data.

@nl

prefLabel

Efficacy and safety profile of ...... port on the emerging new data.

@en

Efficacy and safety profile of ...... port on the emerging new data.

@nl

P1476

Efficacy and safety profile of ...... port on the emerging new data.

@en

P2093

Anne J Kugler

http://www.w3.org/2001/XMLSchema#string

Michael L Thiman

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in the treatment of type 2 diabetes: impact of dulaglutide

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review

Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.

Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

P304

187-197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DMSO.S134960

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29780260

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5951211

http://www.w3.org/2001/XMLSchema#string